Oral pharmaceutical composition for treating capillary leak syndrome

A technology for capillary leakage and syndrome, which can be used in drug combinations, cardiovascular system diseases, blood diseases, etc., and can solve problems such as unclear etiology and lack of therapeutic drugs.

Active Publication Date: 2018-04-24
德州市洛泰商贸有限公司
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Since the exact etiology of capillary leak syndrome is still unclear, there is still a lack of targeted treatment drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Oral pharmaceutical composition for treating capillary leak syndrome
  • Oral pharmaceutical composition for treating capillary leak syndrome
  • Oral pharmaceutical composition for treating capillary leak syndrome

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Example 1 Granules for the treatment of capillary leak syndrome and its preparation

[0024]

[0025] Preparation:

[0026] A: Take rorapitant and pimavanserin tartrate and pass through a 100-mesh sieve respectively, and mix well.

[0027] B: Take lactose, microcrystalline cellulose, and crospovidone to pass through a 100-mesh sieve, and mix well. which milk

[0028] The dosage of sugar is 2.2 times of the weight of rorapitant; the dosage of microcrystalline cellulose is 1.2 times of the weight of rorapitant; the dosage of crospovidone is 0.13 times of the weight of rorapitant.

[0029] C: Mix the powder obtained in step A and step B evenly.

[0030] D: Take povidone K30 and add water and stir well to make a liquid dispersion system. Wherein the consumption of povidone K30 is 0.18 times of the weight of rorapitant; the consumption of water is 32.5 times of the weight of povidone K30.

[0031] E: The liquid dispersion system obtained in step D is added to the pow...

Embodiment 2

[0033] Example 2 Granules for the treatment of capillary leak syndrome and its preparation

[0034]

[0035] Preparation:

[0036] A: Take rorapitant and pimavanserin tartrate and pass through a 100-mesh sieve respectively, and mix well.

[0037] B: Take lactose, microcrystalline cellulose, and crospovidone to pass through a 100-mesh sieve, and mix well. which milk

[0038] The dosage of sugar is 2.2 times of the weight of rorapitant; the dosage of microcrystalline cellulose is 1.2 times of the weight of rorapitant; the dosage of crospovidone is 0.13 times of the weight of rorapitant.

[0039] C: Mix the powder obtained in step A and step B evenly.

[0040] D: Take povidone K30 and add water and stir well to make a liquid dispersion system. Wherein the consumption of povidone K30 is 0.18 times of the weight of rorapitant; the consumption of water is 32.5 times of the weight of povidone K30.

[0041] E: The liquid dispersion system obtained in step D is added to the pow...

Embodiment 3

[0043] Example 3 Granules for the treatment of capillary leak syndrome and its preparation

[0044]

[0045] Preparation:

[0046] A: Take rorapitant and pimavanserin tartrate and pass through a 100-mesh sieve respectively, and mix well.

[0047] B: Take lactose, microcrystalline cellulose, and crospovidone to pass through a 100-mesh sieve, and mix well. which milk

[0048] The dosage of sugar is 2.2 times of the weight of rorapitant; the dosage of microcrystalline cellulose is 1.2 times of the weight of rorapitant; the dosage of crospovidone is 0.13 times of the weight of rorapitant.

[0049] C: Mix the powder obtained in step A and step B evenly.

[0050] D: Take povidone K30 and add water and stir well to make a liquid dispersion system. Wherein the consumption of povidone K30 is 0.18 times of the weight of rorapitant; the consumption of water is 32.5 times of the weight of povidone K30.

[0051] E: The liquid dispersion system obtained in step D is added to the pow...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of medicine, and particularly relates to an oral pharmaceutical composition for treating capillary leak syndrome. The oral pharmaceutical composition is prepared from, by weight, pharmaceutically acceptable excipients, 6-25 parts of rolapitant and 3-9 parts of tartaric acid pimavanserin. The dosage form of the oral pharmaceutical composition is granules preferably. Tartaric acid pimavanserin in the composition has synergistic effect on rolapitant, and rolapitant and tartaric acid pimavanserin have remarkable effect on lowering capillary permeability of a capillary leak syndrome rat model.

Description

technical field [0001] The invention belongs to the field of medicine, in particular to an oral pharmaceutical composition for treating capillary leak syndrome. Background technique [0002] Capillary leak syndrome (Capillary leak syndrome) is a clinical syndrome caused by different reasons, with hypotension, hypoalbuminemia and systemic edema as the main manifestations. The disease is usually critically ill, with complex clinical manifestations, many complications and conflicting fluid therapy. [0003] The exact etiology of capillary leak syndrome is still unclear, but the most common clinical cause of capillary leak syndrome is sepsis. Capillary endothelial cell damage caused by endotoxin and inflammatory mediators may be one of the causes of capillary leak syndrome. Acute lung injury or acute respiratory distress syndrome, severe trauma, and burns can induce the release of systemic inflammatory mediators even if they are local lesions, and this release of inflammatory ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4468A61K31/438A61K9/16A61P9/00A61P7/10A61P7/00
CPCA61K9/1652A61K31/438A61K31/4468A61K2300/00
Inventor 侯瑞玲王金永张玉清
Owner 德州市洛泰商贸有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap